|
Volumn 89, Issue 2, 2002, Pages 192-196
|
Cardiovascular effects of L-158,809, a new angiotensin type 1 receptor antagonist, assessed using the halothane-anesthetized in vivo canine model
a a a a a |
Author keywords
Angiotensin II; L 158,809; QT interval
|
Indexed keywords
2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE;
ANGIOTENSIN;
ANGIOTENSIN 1 RECEPTOR ANTAGONIST;
HALOTHANE;
ANGIOTENSIN II;
ANGIOTENSIN RECEPTOR;
IMIDAZOLE DERIVATIVE;
TETRAZOLE DERIVATIVE;
ANESTHESIA INDUCTION;
ANIMAL EXPERIMENT;
ARTICLE;
CARDIOVASCULAR EFFECT;
CARDIOVASCULAR PARAMETERS;
CONTROLLED STUDY;
DOG;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG INFUSION;
DRUG MEGADOSE;
DRUG POTENCY;
DRUG SELECTIVITY;
IN VIVO STUDY;
INOTROPISM;
NONHUMAN;
PRESSOR RESPONSE;
QT INTERVAL;
STATISTICAL SIGNIFICANCE;
ANIMAL;
ANIMAL MODEL;
BLOOD PRESSURE;
CARDIOVASCULAR SYSTEM;
DRUG ANTAGONISM;
DRUG EFFECT;
METABOLISM;
ANGIOTENSIN II;
ANIMALS;
BLOOD PRESSURE;
CARDIOVASCULAR SYSTEM;
DOGS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HALOTHANE;
IMIDAZOLES;
MODELS, ANIMAL;
RECEPTORS, ANGIOTENSIN;
TETRAZOLES;
|
EID: 0035986323
PISSN: 00215198
EISSN: None
Source Type: Journal
DOI: 10.1254/jjp.89.192 Document Type: Article |
Times cited : (4)
|
References (13)
|